Abiopharma

🔍 Singh Sanjay R (Executive)

Company: MANNKIND CORP (MNKD)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Acquired 221,000 shares of Performance Restricted Stock Unit (Derivative)
  Date: 2026-03-23 | Code: A | equity_swap_involved: false | shares_owned_after: 221,000.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 217,000 shares of Employee Stock Option (right to buy) at $2.44 per share (Derivative)
  Date: 2026-03-23 | Code: A | Expires: 2036-03-23 | Exercise: 2027-03-23 | equity_swap_involved: false | shares_owned_after: 217,000.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
• F2: The performance-based restricted stock unit will vest on January 15, 2029. The number of shares delivered on the vesting date, as a percentage of the target specified [in Box 5 above], is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from April 1, 2026 until December 31, 2028 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the measurement period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
• F3: 25% vesting on March 23, 2027 and thereafter 1/16th quarterly.